Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Insights into the challenges of Lyme disease diagnosis
  • Dependence of Borrelia on host lipids
  • Antiphospholipid antibodies in different diseases
  • Antiphospholipid-specific diagnosis of Lyme disease
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Commentary Open Access | 10.1172/JCI158254

Use of host lipids by the Lyme disease spirochete may lead to biomarkers

Gunjan Arora, Thomas Hart, and Erol Fikrig

Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Address correspondence to: Gunjan Arora, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA. Phone: 203.785.4140; Email: gunjan.arora@yale.edu.

Find articles by Arora, G. in: PubMed | Google Scholar |

Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Address correspondence to: Gunjan Arora, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA. Phone: 203.785.4140; Email: gunjan.arora@yale.edu.

Find articles by Hart, T. in: PubMed | Google Scholar

Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Address correspondence to: Gunjan Arora, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA. Phone: 203.785.4140; Email: gunjan.arora@yale.edu.

Find articles by Fikrig, E. in: PubMed | Google Scholar

Published March 15, 2022 - More info

Published in Volume 132, Issue 6 on March 15, 2022
J Clin Invest. 2022;132(6):e158254. https://doi.org/10.1172/JCI158254.
© 2022 Arora et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published March 15, 2022 - Version history
View PDF

Related article:

Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi
Peter J. Gwynne, … , Adriana R. Marques, Linden T. Hu
Peter J. Gwynne, … , Adriana R. Marques, Linden T. Hu
Research Article Infectious disease Microbiology

Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi

  • Text
  • PDF
Abstract

A close association with its vertebrate and tick hosts allows Borrelia burgdorferi, the bacterium responsible for Lyme disease, to eliminate many metabolic pathways and instead scavenge key nutrients from the host. A lipid-defined culture medium was developed to demonstrate that exogenous lipids are an essential nutrient of B. burgdorferi, which can accumulate intact phospholipids from its environment to support growth. Antibody responses to host phospholipids were studied in mice and humans using an antiphospholipid ELISA. Several of these environmentally acquired phospholipids including phosphatidylserine and phosphatidic acid, as well as borrelial phosphatidylcholine, are the targets of antibodies that arose early in infection in the mouse model. Patients with acute infections demonstrated antibody responses to the same lipids. The elevation of antiphospholipid antibodies predicted early infection with better sensitivity than did the standardized 2-tier tests currently used in diagnosis. Sera obtained from patients with Lyme disease before and after antibiotic therapy showed declining antiphospholipid titers after treatment. Further study will be required to determine whether these antibodies have utility in early diagnosis of Lyme disease, tracking of the response to therapy, and diagnosis of reinfection, areas in which current standardized tests are inadequate.

Authors

Peter J. Gwynne, Luke H. Clendenen, Siu-Ping Turk, Adriana R. Marques, Linden T. Hu

×

Abstract

Lyme disease is the most common tick-borne disease in North America and Europe, however, current biomarkers inconsistently detect the disease. In this issue of the JCI, Gwynne et al. revealed how the Lyme disease agent Borrelia burgdorferi relies on host lipids for growth. The authors used a murine model to show that B. burgdorferi infection led to the production of antibodies against phospholipids, possibly as a consequence of incorporation into the spirochete membrane. Antibodies were induced against phosphatidic acid, phosphatidylcholine, and phosphatidylserine. Notably, no antibodies against cardiolipin were found, distinguishing Lyme disease from syphilis and some other diseases. Sera samples from patients with Lyme disease suggested that these antibodies may help diagnose B. burgdorferi infection and that antibody titers may effectively indicate the response to treatment. These findings suggest that B. burgdorferi–induced anti-lipid antibodies, in conjunction with a careful clinical assessment, may aid in the diagnosis of Lyme disease.

Insights into the challenges of Lyme disease diagnosis

Lyme disease is the most common tick-borne infection in North America (1). Two-tiered serologic testing, consisting of an ELISA followed by immunoblotting against Borrelia antigens, is routinely used to aid clinicians in the diagnosis of Lyme disease. The sensitivity rates, however, are not always ideal, particularly during early infection, when Borrelia burgdorferi–specific antibodies have not yet developed (2, 3). In addition, the long-term presence of B. burgdorferi–specific antibodies after an initial infection can make serodiagnosis of a repeat infection difficult. In this issue of the JCI, Gwynne et al. demonstrate that mice developed antiphospholipid antibodies following B. burgdorferi infection (Figure 1 and ref. 4). Further, the authors found many of the same antibodies in the sera of patients with Lyme disease, mostly in early disease marked by erythema migrans. A further comparison with sera from patients with syphilis implied that some of these antiphospholipid antibodies were specific to B. burgdorferi infection. The findings suggest that antibodies against specific phospholipids could aid in the diagnosis of early or repeat infection by the Lyme disease spirochete.

Model for antiphospholipid antibody production following Borrelia infectionFigure 1

Model for antiphospholipid antibody production following Borrelia infection. Borrelia spirochetes incorporate host lipids into the Borrelia membrane. Subsequently, the host develops antiphospholipid antibodies against PC and PA. Elevated antiphospholipid antibodies may detect Lyme disease at early infection points in human serum.

Dependence of Borrelia on host lipids

The B. burgdorferi membrane includes lipoproteins and lipids, such as phosphatidylcholine (PC), phosphatidylglycerol (PG), and cholesterol (5–8). Because of an evolutionarily reduced genome, B. burgdorferi lack the metabolic pathways to synthesize many required lipids and rely on scavenging lipids from the host environment or culture medium (9). Cholesterol, for example, is taken directly from the host. Cholesterol and cholesterol-glycolipid rafts present on the B. burgdorferi surface can also interact with the lipid rafts of host cells and help Borrelia adhere to cells (10). Lipids are transferred between B. burgdorferi and host cells by direct contact and outer membrane vesicles released by the host (10). Using a delipidated medium, Gwynne et al. showed that B. burgdorferi was unable to grow in the absence of environmental lipids and that this growth was restored when fatty acids and cholesterol were added to the medium (4). The growth was also dependent on the concentration of these fatty acids and cholesterol. While the Borrelia membrane is known to contain PC and PG (11), Gwynne and colleagues revealed that other phospholipids — phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidic acid (PA) — were incorporated into borrelial membranes. Further, the study compared PC uptake in different bacteria and revealed that such uptake was specific to Borrelia and likely acquired by random diffusion. Borrelia lipase (bb0562) contributes to fatty acid scavenging and Borrelia survival under conditions in which free fatty acids are limited (12), but a comprehensive understanding of uptake will require further work. Gwynne and co-authors also demonstrated that the ratio of environmental lipids found in the growth media directly correlated with the proportion of lipids found in the Borrelia membrane (4). This lipid ratio agrees with previous work, demonstrating that Borrelia membrane lipid composition reflects the environmental lipid composition. It stands to reason that the membranes of Borrelia infecting a host would reflect this pattern, whereby the composition of lipids in the host environment would directly relate to the composition of lipids in the infecting Borrelia membrane. Borrelia may scavenge host lipids as a strategy to evade the host immune response directed against Borrelia antigens. The incorporation of host fatty acids into the membrane may allow the spirochetes to evade immune cells patrolling for pathogen lipids, making the spirochetes less immunostimulatory (13–15).

Antiphospholipid antibodies in different diseases

Gwynne and co-authors demonstrate that Borrelia infection may induce antibodies recognizing host phospholipids, revealing a potential biomarker of infection (4). Although antiphospholipid antibodies are most commonly associated with autoimmune disorders, such antibodies are sometimes generated following infection. Syphilis, caused by the spirochete Treponema pallidum, induces antibodies against the phospholipid cardiolipin (16). Interestingly, cardiolipin antibodies are also induced during autoimmune antiphospholipid syndrome (APS). Beyond syphilis, antiphospholipid antibodies have been reported in various infectious diseases including COVID-19, tuberculosis, malaria, leprosy, leptospirosis, and Lyme disease, as well as during Helicobacter pylori, hepatitis C, varicella, and other infections (16, 17). HIV infection is associated with antibodies against cardiolipin as well as PS, PC, and phosphatidylinositol (16, 18). Plasmodium infection similarly induces the development of PS-specific antibodies in mice and humans (19, 20). Such antiphospholipid antibodies are often due to erroneous activation of B cells that are induced because of inflammation and marked by expression of the T-bet transcription factor (21, 22). The broad development of these types of antibodies may limit their overall utility, however, anti-PA, anti-PS, and anti-PC antibodies might be used, in conjunction with a careful clinical assessment and current serologic tests, as biomarkers for Lyme disease.

Antiphospholipid-specific diagnosis of Lyme disease

Gwynne et al. showed that B. burgdorferi infection in a mouse model induced antibodies against PA and PC and against the phospholipids PS, PE, PG, and galactosylcholesterol (gC) (4). The mice did not develop antibodies against cardiolipin, the phospholipid associated with syphilis infection, implying that the detected antibodies were specific to Lyme disease. The authors then compared the diagnostic value of PA-, PS- and PC-specific antibody responses using standard assays in patients with early symptoms of Lyme disease. In a small number of patients, the diagnosis using antiphospholipid antibodies outperformed standard diagnostic tests and even correctly identified antibody responses in individuals who only presented with erythema migrans. In addition, the antiphospholipid antibodies peaked during B. burgdorferi infection in humans and declined following antibiotic treatment, which contrasts with the more prolonged antibody response toward Borrelia antigens. These antiphospholipid responses could depend on invariant natural killer T (iNKT) cells, which are capable of recognizing lipid antigens and assisting B cells with antibody production (23, 24). Future studies to validate antiphospholipid responses with B. burgdorferi infection should include a larger number of patients with Lyme disease and individuals with other infectious and autoimmune illnesses. The lipid autoantibodies described in the study by Gwynne and colleagues represent potentially promising biomarkers that could aid clinicians in the diagnosis of Lyme disease and meaningfully impact patient outcomes.

Acknowledgments

This work was support by grants from the NIH (AI126033 and AI138949, to EF).

Address correspondence to: Gunjan Arora, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA. Phone: 203.785.4140; Email: gunjan.arora@yale.edu.

Footnotes

Conflict of interest: EF has an equity interest in and serves as a consultant for L2 Diagnostics.

Copyright: © 2022, Arora et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2022;132(6):e158254. https://doi.org/10.1172/JCI158254.

See the related article at Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi.

References
  1. Mead PS. Epidemiology of Lyme disease. Infect Dis Clin North Am. 2015;29(2):187–210.
    View this article via: CrossRef PubMed Google Scholar
  2. Leeflang MM, et al. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:140.
    View this article via: CrossRef PubMed Google Scholar
  3. Schutzer SE, et al. Direct diagnostic tests for Lyme disease. Clin Infect Dis. 2019;68(6):1052–1057.
    View this article via: CrossRef PubMed Google Scholar
  4. Gwynne PJ, et al. Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi. J Clin Invest. 2022;132(6):e152506.
    View this article via: JCI CrossRef Google Scholar
  5. Wang XG, et al. Phospholipid synthesis in Borrelia burgdorferi: BB0249 and BB0721 encode functional phosphatidylcholine synthase and phosphatidylglycerolphosphate synthase proteins. Microbiology (Reading). 2004;150(pt 2):391–397.
    View this article via: PubMed Google Scholar
  6. Ben-Menachem G, et al. A newly discovered cholesteryl galactoside from Borrelia burgdorferi. Proc Natl Acad Sci U S A. 2003;100(13):7913–7918.
    View this article via: CrossRef PubMed Google Scholar
  7. Hove PR, et al. Identification and functional analysis of a galactosyltransferase capable of cholesterol glycolipid formation in the Lyme disease spirochete Borrelia burgdorferi. PLoS One. 2021;16(6):e0252214.
    View this article via: CrossRef PubMed Google Scholar
  8. Huang Z, London E. Cholesterol lipids and cholesterol-containing lipid rafts in bacteria. Chem Phys Lipids. 2016;199:11–16:S0009-3084(16)30036–6.
    View this article via: PubMed Google Scholar
  9. Ye M, et al. Genome reduction of Borrelia burgdorferi: two TCS signaling pathways for two distinct host habitats. Sci China Life Sci. 2016;59(1):19–21.
    View this article via: CrossRef PubMed Google Scholar
  10. Crowley JT, et al. Lipid exchange between Borrelia burgdorferi and host cells. PLoS Pathog. 2013;9(1):e1003109.
    View this article via: CrossRef PubMed Google Scholar
  11. Hossain H, et al. Structural analysis of glycolipids from Borrelia burgdorferi. Biochimie. 2001;83(7):683–692.
    View this article via: CrossRef PubMed Google Scholar
  12. Kuhn HW, et al. BB0562 is a nutritional virulence determinant with lipase activity important for Borrelia burgdorferi infection and survival in fatty acid deficient environments. PLoS Pathog. 2021;17(8):e1009869.
    View this article via: CrossRef PubMed Google Scholar
  13. Toledo A, Benach JL. Hijacking and use of host lipids by intracellular pathogens. Microbiol Spectr. 2015;3(6)
    View this article via: PubMed Google Scholar
  14. Wolf BJ, et al. Identification of a potent microbial lipid antigen for diverse NKT cells. J Immunol. 2015;195(6):2540–2551.
    View this article via: CrossRef PubMed Google Scholar
  15. Birge RB, et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016;23(6):962–978.
    View this article via: CrossRef PubMed Google Scholar
  16. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62(5):388–393.
    View this article via: CrossRef PubMed Google Scholar
  17. Stelzer M, et al. The role of antiphospholipid antibodies in COVID-19. Curr Rheumatol Rep. 2021;23(9):72.
    View this article via: CrossRef PubMed Google Scholar
  18. Silvestris F, et al. Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity. Blood. 1996;87(12):5185–5195.
    View this article via: CrossRef PubMed Google Scholar
  19. Barber BE, et al. Antiphosphatidylserine immunoglobulin M and immunoglobulin G antibodies are higher in vivax than falciparum malaria, and associated with early anemia in both species. J Infect Dis. 2019;220(9):1435–1443.
    View this article via: CrossRef PubMed Google Scholar
  20. Fernandez-Arias C, et al. Anti-self phosphatidylserine antibodies recognize uninfected erythrocytes promoting malarial anemia. Cell Host Microbe. 2016;19(2):194–203.
    View this article via: CrossRef PubMed Google Scholar
  21. Peng SL, et al. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A. 2002;99(8):5545–5550.
    View this article via: CrossRef PubMed Google Scholar
  22. Rivera-Correa J, et al. Plasmodium DNA-mediated TLR9 activation of T-bet+ B cells contributes to autoimmune anaemia during malaria. Nat Commun. 2017;8(1):1282.
    View this article via: CrossRef PubMed Google Scholar
  23. King IL, et al. Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner. Nat Immunol. 2011;13(1):44–50.
    View this article via: PubMed Google Scholar
  24. Brennan PJ, et al. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13(2):101–117.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (March 15, 2022): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Insights into the challenges of Lyme disease diagnosis
  • Dependence of Borrelia on host lipids
  • Antiphospholipid antibodies in different diseases
  • Antiphospholipid-specific diagnosis of Lyme disease
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts